SSAs play an additional pivotal role in CHD treatment in order to reduce 5-HIAA levels, along with conventional medical therapy including diuretics, mineralocorticoid receptor antagonists and cautious fluid replacement. Here, NR3C2 is linked to coronary artery disorder.